Googles Shweta Maniar writes about what shes learned traveling to conferences across the planet to talk about the convergence ...

Non-hallucinogenic neuroplastogens offer benefits over classical psychedelics, including simpler delivery, stronger IP ...

As new therapies for obesity enter the market, biopharmaceutical companies will need to tune commercial strategies to win ...

Biotechnology is all about scientific breakthroughs that lead to transformative therapies. But despite billions invested and years of R&D, data from Deloitte found that more than half of drug launches ...

Crystalline forms of compounds and salts are frequently claimed in chemical patents, including in pharmaceuticals and agrochemicals. Different crystalline forms of the same substance — that is, ...

Proper legal structuring is essential when it comes to transferring Chinese biotech intellectual property and clinical assets to form a U.S.-based Newco, explain experts at Orrick.

After decades of racing to the bottom on pricing, a revolution is coming to the U.S. generics market, writes Yaral Pharma CEO Stephen Beckman.

Advocacy for alternatives to animal testing in clinical research is pushing the industry away from animal-based endotoxin testing. Charles River Labs Nicola Reid lays out the issues to consider.

Experts at Faegre Drinker offer life sciences business planning and risk mitigation strategies to consider in response to enacted or anticipated policy changes under the Trump administration.

Modern drug development approaches that integrate functional plans with larger business goals are needed for success in early and late-stage drug development, explains Hallorans Carolina Ahrendt.

Essential medicines play a vital role in America’s health, and the supply is closely monitored by the FDA and industry groups. These medicines sustain life, provide life support and/or the prevention ...

Denise Bronner, Ph.D., makes the case for and against acquisitions for rejuvenating Big Pharma pipelines. She explains why outsourcing innovation can be as risky, and costly, as internal discovery.